“…The seven identified drugs plus mannitol in their data set included Class 1 high extraction ratio drugs (metoprolol, propranolol, and verapamil), which of course would be expected to show low bioavailability; BDDCS Class 2 intermediate to low extraction ratio compounds (indomethacin, carbamazepine and warfarin), which would be expected to show intermediate to high bioavailability; timolol (probably BDDCS Class 2), a compound with higher clearance than the other Class 2 compounds, but less than the Class 1 compounds, and therefore expected to have intermediate bioavailability among these 7 drugs; and finally only one unmetabolized substance, mannitol (probably BDDCS Class 3), with very poor permeability, that would be expected to show poor bioavailability. So in essence, this report (53) just confirms the finding of Smith (19) that more permeable lipophilic compounds make good substrates for CYP enzymes, as the fraction not metabolized in 30 min of incubation is a measure of clearance, but the method will not be able to account for differences in bioavailability for Class 2 compounds that result from transporter-enzyme interplay, or for Class 3 drugs where uptake transporters will be the defining determinant of bioavailability. As outlined here, incorporation of recent scientific understanding should allow the pharmaceutical sciences community to develop a DPR parameter with predictability [i.e., it is not true that permeability of 80% of all compounds is due to passive diffusion; hepatocytes (or some other system that maintains the architecture of transporters and enzymes) should be used for the metabolism studies, not microsomes or the S9 fraction, so to include transporter-enzyme interplay; the fraction of total clearance that is attributable to metabolism rather than the metabolic clearance is the "permeability" parameter that differentiates BDDCS classes; both influx and efflux transporters must be considered; although clearance is a reasonable predictor of bioavailability for Class 1 compounds, this will often not be true for drugs from Classes 2, 3 and 4 where transporters cause differential effects between a Solubility classification was predominantly gathered from the literature (1,(3)(4)(5)(6)(7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18).…”